ADPT · NASDAQ
Adaptive Biotechnologies Corporation
$28.25 +0.73 (+2.91%)
Company overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product used to answer translational research questions and to discover new prognostic and diagnostic signals, and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $4.5B
- Employees
- 619
- Headquarters
- Seattle, WA
- Website
- adaptivebiotech.com
- CEO
- Chad Robins
- Listed
- June 27, 2019
- P/E
- -86.29
- Dividend yield
- 0.00%
Company financials
- Revenue
- $295M
- Gross profit
- $222M
- Operating income
- -$46.7M
- EBITDA
- -$22M
- Net income
- -$49.7M
- EPS
- -$0.33
- Total assets
- $506M
- Total debt
- $208M
- Gross margin
- 75.26%
- Net margin
- -16.82%
- Earnings yield
- -1.16%
No geographic segmentation.
Showing FY 2021
ADPT
1D
NASDAQ
O25.46H26.46L25.33C25.80+0.74 (+2.95%)Vol1.51M
News